TY - JOUR T1 - A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 1009 LP - 1014 DO - 10.1136/ard.2003.017673 VL - 63 IS - 9 AU - E Hachulla AU - J G Coghlan Y1 - 2004/09/01 UR - http://ard.bmj.com/content/63/9/1009.abstract N2 - Evidence suggests that endothelin may have a fundamental role in scleroderma pathogenesis, including pulmonary arterial hypertension (PAH)—a leading cause of death in patients with scleroderma. Development of a new class of drug, endothelin receptor antagonists, heralds an improved outlook for patients with scleroderma and related diseases. Heightened vigilance towards early detection of PAH in scleroderma and a multidisciplinary approach to diagnosis and treatment may improve clinical outcomes for these patients. ER -